Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response correctly matches some high-level label content (indications, mechanism, TB/vaccination completion concept). However, it makes multiple immunization timing claims (“at any time” for influenza/Tdap/PCV; specific 2–4 and 4–6 week waiting periods for zoster and HPV) that are not supported by the provided labeling excerpts and may conflict with the label’s general requirement to consider completion of age-appropriate immunizations and avoid live vaccines.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported by indications provided: plaque psoriasis (1.1), psoriatic arthritis (1.2), and ankylosing spondylitis (1.3).
Cosentyx works by blocking the action of interleukin-17A (IL-17A).
Supported by 11 Description/12.1 mechanism: secukinumab is an IL-17A antagonist that selectively binds IL-17A and inhibits its interaction with the IL-17 receptor.
Cosentyx, like other biologics, can suppress the immune system.
Partially supported by 5.1 Immunizations: COSENTYX may alter immune response to live vaccines, and 5.1 Infections: may increase risk of infections. (The response wording “suppress the immune system” is not exact label phrasing but aligns with the concept of altered immune response/infection risk.)
No waiting period is required between Cosentyx and an influenza vaccine; the influenza vaccine can be administered at any time.
Not supported by the provided excerpts (see unsupported statements).
Unsupported Statements
No waiting period is required between Cosentyx and an influenza vaccine; the influenza vaccine can be administered at any time.
Provided label excerpt 5.7 states to consider completion of age-appropriate immunizations prior to initiating COSENTYX and that COSENTYX may alter immune response to live vaccines and to avoid live vaccines. It does not provide a claim that influenza vaccine can be administered at any time or specify any waiting period.
No waiting period is required between Cosentyx and a Tdap (tetanus, diphtheria, pertussis) vaccine; the Tdap vaccine can be administered at any time.
The provided excerpts only provide general immunization guidance (5.7) and do not mention Tdap timing or a “no waiting period/any time” rule.
No waiting period is required between Cosentyx and a pneumococcal conjugate (PCV) vaccine; the PCV vaccine can be administered at any time.
The provided excerpts do not provide any vaccine-specific timing guidance for PCV.
A waiting period of 2-4 weeks is recommended between Cosentyx and a zoster vaccine to ensure the vaccine's effectiveness.
The provided label excerpt 5.7 does not specify a 2–4 week waiting period for zoster vaccination.
A waiting period of 4-6 weeks is recommended between Cosentyx and an HPV (human papillomavirus) vaccine to ensure the vaccine's effectiveness.
The provided label excerpt 5.7 does not specify a 4–6 week waiting period for HPV vaccination.
Contradictions
Low
AI Statement
No waiting period is required between Cosentyx and an influenza vaccine; the influenza vaccine can be administered at any time.
Label Reference
5.7 Immunizations: COSENTYX may alter a patient's immune response to live vaccines; avoid use of live vaccines in patients treated with COSENTYX. The label excerpt does not support the implied “at any time” generalization, and could be inconsistent depending on whether the referenced vaccine is live.
Important Omissions
For any immunization timing claims, the label excerpt emphasizes general pre-treatment completion of age-appropriate immunizations and avoidance of live vaccines during COSENTYX treatment, but the response did not mention these constraints.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Immunization timing claims are not supported by the provided labeling excerpts and omit the label’s general instruction to avoid live vaccines and consider completion of age-appropriate immunizations prior to starting COSENTYX.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Vaccine-specific timing (“at any time” and fixed week waiting periods) is not supported by the provided COSENTYX prescribing information excerpt (5.7), which instead provides general guidance and a live-vaccine avoidance requirement.
Suggested Improvement
Replace vaccine-specific timing and fixed waiting-period recommendations with the label’s general immunization guidance: consider completion of all age-appropriate immunizations prior to initiating COSENTYX and avoid live vaccines in patients treated with COSENTYX.